Oct 26, 2023 7:00am EDT Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Oct 09, 2023 7:00am EDT Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
Sep 27, 2023 7:00am EDT Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Sep 07, 2023 7:00am EDT Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
Aug 31, 2023 7:00am EDT Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Aug 24, 2023 7:10am EDT Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
Aug 18, 2023 7:00am EDT Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
Jul 17, 2023 7:00am EDT Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Jun 29, 2023 7:00am EDT Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
